Home › Hypoglycemia › NCT06470295
Effect of C-peptide on Hypoglycemic Counterregulation
On the Regulation of Hepatic Glucose Metabolism During Insulin-induced Hypoglycemia
Who can join
Ages 18 to 40 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * BMI less than 30 kg/m2 Exclusion Criteria: * pregnant or lactating women cigarette smoking presence of HIV or hepatitis presence of cardiovascular disease presence of microvascular disease
About the study
Iatrogenic hypoglycemia is the most prominent barrier to the safe, effective management of blood sugar in people with type 1 diabetes due to periodic over-insulinization. During insulin-induced hypoglycemia, glucagon secretion is diminished in type 1 diabetes which, in turn, reduces hepatic glucose production and increases the depth and duration of hypoglycemic episodes. We have observed that the naturally occurring protein C-peptide increases glucagon secretion in dogs during insulin-induced hypoglycemia, which increases hepatic glucose production; the experiments in this application will shed light on the translation of this finding to the human.
What is being tested
- Saline (other)
- C-peptide (biological)
Sponsor: University of Cincinnati · Participants: 38 · Started: Jun 1, 2024
Contact the study team
- Jason Winnick, PhD · Phone: 513-558-4437
- Natalie Whitsett · Phone: 513-558-4489
Official record on ClinicalTrials.gov — NCT06470295
Locations in the U.S.
| Ohio | University of Cincinnati, Cincinnati |
Conditions
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.